Literature DB >> 16772343

Prevalence of RET/PTC rearrangements in thyroid papillary carcinomas: effects of the detection methods and genetic heterogeneity.

Zhaowen Zhu1, Raffaele Ciampi, Marina N Nikiforova, Manoj Gandhi, Yuri E Nikiforov.   

Abstract

CONTEXT: RET/PTC rearrangements have been reported in papillary thyroid carcinomas with variable frequency in studies that used different detection methods.
OBJECTIVE: Our objective was to determine the role of different detection methods and tumor genetic heterogeneity on RET/PTC detection.
DESIGN: Sixty-five papillary carcinomas were analyzed for RET/PTC1 and RET/PTC3 using five detection methods: standard-sensitivity RT-PCR, high-sensitivity RT-PCR, real-time LightCycler RT-PCR, Southern blot analysis, and fluorescence in situ hybridization.
RESULTS: RET/PTC rearrangements were detected by standard-sensitivity RT-PCR in 14 tumors. High-sensitivity RT-PCR detected RET/PTC in all of these and in 12 additional cases, where the levels of expression corresponded to one to five positive cells. Real-time LightCycler RT-PCR detected RET/PTC in 12 and Southern blot analysis in 11 tumors. By fluorescence in situ hybridization, 14 tumors were positive, including nine cases with 50-86% positive cells and five cases with 17-35% positive cells. Overall, nine (14%) tumors harbored clonal rearrangements, which were present in the majority of tumor cells and detected by all five methods. Five (8%) cases had subclonal rearrangements present in a smaller portion of tumor cells and detected by most methods. Twelve (18%) tumors had nonclonal RET/PTC that were detected only by high-sensitivity RT-PCR. No other mutations were found in tumors harboring clonal RET/PTC, whereas 60% of tumors with subclonal and 42% of tumors with nonclonal RET/PTC harbored additional mutations.
CONCLUSIONS: Our data suggest that broad variability in the reported prevalence of RET/PTC rearrangement is at least in part a result of the use of different detection methods and tumor genetic heterogeneity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16772343     DOI: 10.1210/jc.2006-1006

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  55 in total

1.  BRAFV600E mutation and papillary thyroid cancer: chicken or egg?

Authors:  Mingzhao Xing
Journal:  J Clin Endocrinol Metab       Date:  2012-07       Impact factor: 5.958

Review 2.  The discovery and development of sorafenib for the treatment of thyroid cancer.

Authors:  Peter T White; Mark S Cohen
Journal:  Expert Opin Drug Discov       Date:  2015-02-08       Impact factor: 6.098

Review 3.  Molecular pathology of thyroid cancer: diagnostic and clinical implications.

Authors:  James A Fagin; Nicholas Mitsiades
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2008-12       Impact factor: 4.690

4.  Mutation in BRAF and Other Members of the MAPK Pathway in Papillary Thyroid Carcinoma in the Pediatric Population.

Authors:  Ryan J Gertz; Yuri Nikiforov; William Rehrauer; Lee McDaniel; Ricardo V Lloyd
Journal:  Arch Pathol Lab Med       Date:  2016-02       Impact factor: 5.534

Review 5.  Molecular markers in well-differentiated thyroid cancer.

Authors:  Anil K D'Cruz; Richa Vaish; Abhishek Vaidya; Iain J Nixon; Michelle D Williams; Vincent Vander Poorten; Fernando López; Peter Angelos; Ashok R Shaha; Avi Khafif; Alena Skalova; Alessandra Rinaldo; Jennifer L Hunt; Alfio Ferlito
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-04-06       Impact factor: 2.503

6.  Prevalence of RET/PTC1 and RET/PTC3 gene rearrangements in Chennai population and its correlation with clinical parameters.

Authors:  P Jagan Mohan Rao; N V Vardhini; M V S Parvathi; P Balakrishna Murthy; G Sudhakar
Journal:  Tumour Biol       Date:  2014-06-24

7.  RET/PTC and PAX8/PPARγ chromosomal rearrangements in post-Chernobyl thyroid cancer and their association with iodine-131 radiation dose and other characteristics.

Authors:  Rebecca J Leeman-Neill; Alina V Brenner; Mark P Little; Tetiana I Bogdanova; Maureen Hatch; Liudmyla Y Zurnadzy; Kiyohiko Mabuchi; Mykola D Tronko; Yuri E Nikiforov
Journal:  Cancer       Date:  2013-02-21       Impact factor: 6.860

8.  Papillary thyroid carcinoma in a 5-year-old child-case report.

Authors:  B N Gayathri; A Sagayaraj; S Prabhakara; T N Suresh; Merchant Shuaib; S M Azeem Mohiyuddin
Journal:  Indian J Surg Oncol       Date:  2014-03-11

9.  High rate of BRAF and RET/PTC dual mutations associated with recurrent papillary thyroid carcinoma.

Authors:  Ying C Henderson; Thomas D Shellenberger; Michelle D Williams; Adel K El-Naggar; Mitchell J Fredrick; Kathleen M Cieply; Gary L Clayman
Journal:  Clin Cancer Res       Date:  2009-01-15       Impact factor: 12.531

Review 10.  Central role of RET in thyroid cancer.

Authors:  Massimo Santoro; Francesca Carlomagno
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-12-01       Impact factor: 10.005

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.